Pan Cancer T develops natural affinity TCR T cell therapies towards unique and proprietary intracellular targets expressed by multiple solid tumors
Employees: 1-10
Total raised: $16.3M
Founded date: 2020
Investors 1
| Date | Name | Website |
| 12.02.2021 | Swanbridge... | swanbridge... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 08.12.2025 | - | $11.69M | - |
| 11.07.2024 | Seed | $4.6M | - |
Mentions in press and media 8
| Date | Title | Description |
| 08.12.2025 | Pan Cancer T Raises €10M in Funding | Pan Cancer T, a Rotterdam, the Netherlands-based biotech company developing T cell therapies for solid tumours, raised €10M in funding. The round included €5M from existing investors Van Herk Ventures, Thuja Capital, Erasmus MC O&O Hold... |
| 29.07.2024 | EIT Health Catapult finalist “Pan Cancer T” closes a €4 million seed extension funding round (Sponsored) | Building a successful healthcare startup is fraught with challenges, from navigating regulatory hurdles to securing substantial funding for clinical translation. While early-stage investment in Europe has accelerated, significant gaps remai... |
| 13.07.2024 | Pan Cancer T Secures Funding to Revolutionize Cancer Treatment | In a significant development in the field of cancer treatment, Pan Cancer T, a pioneering biotech startup based in Rotterdam, the Netherlands, has successfully closed a Seed Extension funding round, raising an impressive €4.25 million. This... |
| 11.07.2024 | Pan Cancer T Raises €4.25M in Seed Extension Funding | Pan Cancer T, a Rotterdam, the Netherlands-based biotech startup developing T cell therapies for solid cancer treatment, raised €4.25M in Seed extension funding. The round, which brought the total amount to approx. €11M, was led by Innovati... |
| 11.07.2024 | Pan Cancer T secures €4.25 Million in Seed Extension Round to advance next-generation T cell therapies | ROTTERDAM, the Netherlands, July 11, 2024 (GLOBE NEWSWIRE) -- Pan Cancer T B.V., a pioneering biotech start-up developing next-generation T cell therapies for solid cancer treatment, has successfully closed a €4.25 million Seed Extension ro... |
| 23.11.2022 | Pan Cancer T and NecstGen Collaborate to Accelerate Novel TCR-T Therapies into Clinical Development | Pan Cancer T B.V., and NecstGen B.V., today announced a partnership to advance Pan Cancer T’s innovative therapies into the clinic. LEIDEN, SOUTH HOLLAND, THE NETHERLANDS, November 23, 2022 /EINPresswire.com/ -- Pan Cancer T B.V., a biotech... |
| - | Pan Cancer | “Pan Cancer T | Targeting Tougher Tumours” |
| - | Pan Cancer | “Pan Cancer T is an immunotherapy company developing next-generation TCR-T cell therapies for solid cancer.” |